Fig. 1From: Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 studyStudy flowchart. ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; QD, quaque die; BID, bis in dieBack to article page